Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030
The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.
The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.
“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”
By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.
“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”
The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.
“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”
The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.
A breakdown of the primary participants referred to for this report is provided below:Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).
Research Coverage
This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.
Reasons to Buy the Report
The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.
This report provides insights into the following pointers:
The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.
“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”
By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.
“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”
The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.
“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”
The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30%
- By Designation: C Level: 30%, Director Level: 34%, and Others: 36%
- By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).
Research Coverage
This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.
Reasons to Buy the Report
The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.
This report provides insights into the following pointers:
- Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 List of key secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key objectives of primary research
2.1.2.2 List of primary sources
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.1.2.5 Insights from industry experts
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Revenue estimation of key players
2.2.1.2 Study of annual reports and investor presentations
2.2.1.3 Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 STUDY ASSUMPTIONS
2.4.1 RESEARCH-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.4.3 GROWTH-RATE ASSUMPTIONS
2.4.4 MARKET ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET
4.2 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024
4.3 NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.4 NEUROMODULATION MARKET: REGIONAL MIX
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
5.2.1.2 High incidence of neurological disorders among geriatric population
5.2.1.3 Favorable government support and funding with advanced healthcare infrastructure
5.2.1.4 Development of advanced neuromodulation and neurostimulation technologies
5.2.1.5 Growing collaborations among device manufacturers, healthcare providers, and research institutions
5.2.1.6 Availability of reimbursements for neuromodulation devices
5.2.2 RESTRAINTS
5.2.2.1 High cost of neuromodulation procedures
5.2.2.2 Preference for drug therapies over neuromodulation products
5.2.2.3 Adverse effects and complications with neuromodulation devices
5.2.3 OPPORTUNITIES
5.2.3.1 Large population and high healthcare expenditure in emerging economies
5.2.3.2 Widening application scope of neuromodulation
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
5.2.4.2 Shortage of trained professionals
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025
5.4.2 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025
5.4.3 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Transcutaneous electrical nerve stimulation
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Wearable biosensors
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Regenerative medicine and stem cells
5.10 PATENT ANALYSIS
5.10.1 LIST OF KEY PATENTS
5.11 TRADE DATA ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 901890
5.11.2 EXPORT DATA FOR HS CODE 901890
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 CASE STUDY ANALYSIS
5.13.1 USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH, CLINICAL PRACTICE, AND CONSUMER APPLICATIONS
5.13.2 PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS
5.13.3 APPLICATION OF NEUROMODULATION TECHNIQUES—FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION
5.14 REGULATORY ANALYSIS
5.14.1 REGULATORY LANDSCAPE
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER’S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 KEY BUYING CRITERIA
5.17 IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET
5.17.1 INTRODUCTION
5.17.2 POTENTIAL OF AI
5.17.3 IMPACT OF AI
5.17.4 KEY COMPANIES IMPLEMENTING AI
5.17.5 FUTURE OF AI
5.18 IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals
6 NEUROMODULATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 INTERNAL NEUROMODULATION
6.2.1 INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT RESULTS AND LOWER HEALTHCARE COSTS
6.3 EXTERNAL NEUROMODULATION
6.3.1 RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL AND PAIN-RELATED DISORDERS TO FUEL GROWTH
7 NEUROMODULATION MARKET, BY STIMULATION TYPE
7.1 INTRODUCTION
7.2 SPINAL CORD STIMULATION
7.2.1 GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH
7.3 DEEP BRAIN STIMULATION
7.3.1 MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS
7.4 SACRAL NERVE STIMULATION
7.4.1 INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH
7.5 VAGUS NERVE STIMULATION
7.5.1 RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY
7.6 GASTRIC NERVE STIMULATION
7.6.1 INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
7.7.1 LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR
7.8 TRANSCRANIAL MAGNETIC STIMULATION
7.8.1 MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND
7.9 RESPIRATORY ELECTRICAL STIMULATION
7.9.1 HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH
7.10 OTHER STIMULATION TYPES
8 NEUROMODULATION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION
8.2.1 CHRONIC PAIN
8.2.1.1 High incidence of chronic pain among geriatric population to support market growth
8.2.2 FAILED BACK SURGERY SYNDROME
8.2.2.1 Increasing number of spinal surgeries to aid market growth
8.2.3 ISCHEMIA
8.2.3.1 High effectiveness of neuromodulation to boost effectiveness for ischemia treatment
8.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION
8.3.1 PARKINSON’S DISEASE
8.3.1.1 Development of advanced solutions and increased R&D to improve market growth
8.3.2 TREMORS
8.3.2.1 Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market
8.3.3 DEPRESSION
8.3.3.1 Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment
8.3.4 OTHER DEEP BRAIN STIMULATION APPLICATIONS
8.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION
8.4.1 URINE INCONTINENCE
8.4.1.1 High incidence of urine incontinence to offer growth opportunities for market players
8.4.2 FECAL INCONTINENCE
8.4.2.1 Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence
8.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION
8.5.1 EPILEPSY
8.5.1.1 Low risk with device implantation and long-lasting battery life to aid market growth
8.5.2 OTHER VAGUS NERVE STIMULATION APPLICATIONS
8.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
8.6.1 GASTROPARESIS
8.6.1.1 Reduced hospitalization time associated with sastroparesis treatment to augment market growth
8.6.2 OBESITY
8.6.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market growth
8.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
8.7.1 TREATMENT-RESISTANT DEPRESSION
8.7.1.1 High prevalence of chronic and recurrent depression to augment market growth
8.7.2 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS
8.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
8.8.1 DEPRESSION
8.8.1.1 Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients
8.8.2 MIGRAINE
8.8.2.1 High prevalence of migraines to support market growth
8.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
8.9.1 INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS
8.10 OTHER APPLICATIONS
9 NEUROMODULATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & AMBULATORY SURGERY CENTERS
9.2.1 ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH
9.3 CLINICS & PHYSIOTHERAPY CENTERS
9.3.1 NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION
9.4 OTHER END USERS
10 NEUROMODULATION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American neuromodulation market during forecast period
10.2.3 CANADA
10.2.3.1 Increasing neurological disorder rates and rising government funding to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Advanced surgical innovations and favorable reimbursement policies to drive market
10.3.3 FRANCE
10.3.3.1 Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques
10.3.4 UK
10.3.4.1 Increased public & private sector healthcare expenditure and investments to fuel market growth
10.3.5 ITALY
10.3.5.1 Rising cases of dementia and Alzheimer’s among geriatric population to spur market growth
10.3.6 SPAIN
10.3.6.1 Favorable government-led healthcare initiatives to support market growth
10.3.7 RUSSIA
10.3.7.1 Shifting demographic landscape and escalating neurological health needs to drive demand
10.3.8 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand
10.4.3 JAPAN
10.4.3.1 Innovative healthcare delivery and advanced infrastructure landscape to augment market growth
10.4.4 INDIA
10.4.4.1 Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth
10.4.5 AUSTRALIA
10.4.5.1 Increasing cases of depressive and post-traumatic stress disorders to propel market demand
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Improvements in healthcare infrastructure to aid market growth
10.5.3 MEXICO
10.5.3.1 Expanding healthcare awareness and growing burden of neurological disorders to favor market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET
11.3 REVENUE ANALYSIS, 2020–2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Technology footprint
11.5.5.4 Stimulation type footprint
11.5.5.5 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of startups/SMEs
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 COMPANY VALUATION
11.7.2 FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MEDTRONIC
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 BOSTON SCIENTIFIC CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 ABBOTT
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches and approvals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 LIVANOVA PLC
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 NEVRO CORP.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 NEUROPACE, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 BIOVENTUS
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product approvals
12.1.8 ELECTROCORE, INC.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.8.3.2 Deals
12.1.9 HELIUS MEDICAL TECHNOLOGIES, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.10 NEURONETICS
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Deals
12.2 OTHER PLAYERS
12.2.1 NEUROSIGMA, INC.
12.2.2 SOTERIX MEDICAL INC.
12.2.3 SYNAPSE BIOMEDICAL INC.
12.2.4 ALEVA NEUROTHERAPEUTICS
12.2.5 THERANICA BIO-ELECTRONICS LTD.
12.2.6 GIMER MEDICAL
12.2.7 NALU MEDICAL, INC.
12.2.8 MICROTRANSPONDER INC.
12.2.9 MAGSTIM
12.2.10 AMBER THERAPEUTICS
12.2.11 TVNS TECHNOLOGIES GMBH
12.2.12 BIOWAVE
12.2.13 BIOTRONIK
12.2.14 SALUDA MEDICAL PTY LTD.
12.2.15 SPR
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 List of key secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key objectives of primary research
2.1.2.2 List of primary sources
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.1.2.5 Insights from industry experts
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Revenue estimation of key players
2.2.1.2 Study of annual reports and investor presentations
2.2.1.3 Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 STUDY ASSUMPTIONS
2.4.1 RESEARCH-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.4.3 GROWTH-RATE ASSUMPTIONS
2.4.4 MARKET ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET
4.2 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024
4.3 NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.4 NEUROMODULATION MARKET: REGIONAL MIX
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
5.2.1.2 High incidence of neurological disorders among geriatric population
5.2.1.3 Favorable government support and funding with advanced healthcare infrastructure
5.2.1.4 Development of advanced neuromodulation and neurostimulation technologies
5.2.1.5 Growing collaborations among device manufacturers, healthcare providers, and research institutions
5.2.1.6 Availability of reimbursements for neuromodulation devices
5.2.2 RESTRAINTS
5.2.2.1 High cost of neuromodulation procedures
5.2.2.2 Preference for drug therapies over neuromodulation products
5.2.2.3 Adverse effects and complications with neuromodulation devices
5.2.3 OPPORTUNITIES
5.2.3.1 Large population and high healthcare expenditure in emerging economies
5.2.3.2 Widening application scope of neuromodulation
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
5.2.4.2 Shortage of trained professionals
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025
5.4.2 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025
5.4.3 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Transcutaneous electrical nerve stimulation
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Wearable biosensors
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Regenerative medicine and stem cells
5.10 PATENT ANALYSIS
5.10.1 LIST OF KEY PATENTS
5.11 TRADE DATA ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 901890
5.11.2 EXPORT DATA FOR HS CODE 901890
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 CASE STUDY ANALYSIS
5.13.1 USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH, CLINICAL PRACTICE, AND CONSUMER APPLICATIONS
5.13.2 PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS
5.13.3 APPLICATION OF NEUROMODULATION TECHNIQUES—FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION
5.14 REGULATORY ANALYSIS
5.14.1 REGULATORY LANDSCAPE
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER’S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 KEY BUYING CRITERIA
5.17 IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET
5.17.1 INTRODUCTION
5.17.2 POTENTIAL OF AI
5.17.3 IMPACT OF AI
5.17.4 KEY COMPANIES IMPLEMENTING AI
5.17.5 FUTURE OF AI
5.18 IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals
6 NEUROMODULATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 INTERNAL NEUROMODULATION
6.2.1 INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT RESULTS AND LOWER HEALTHCARE COSTS
6.3 EXTERNAL NEUROMODULATION
6.3.1 RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL AND PAIN-RELATED DISORDERS TO FUEL GROWTH
7 NEUROMODULATION MARKET, BY STIMULATION TYPE
7.1 INTRODUCTION
7.2 SPINAL CORD STIMULATION
7.2.1 GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH
7.3 DEEP BRAIN STIMULATION
7.3.1 MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS
7.4 SACRAL NERVE STIMULATION
7.4.1 INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH
7.5 VAGUS NERVE STIMULATION
7.5.1 RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY
7.6 GASTRIC NERVE STIMULATION
7.6.1 INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
7.7.1 LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR
7.8 TRANSCRANIAL MAGNETIC STIMULATION
7.8.1 MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND
7.9 RESPIRATORY ELECTRICAL STIMULATION
7.9.1 HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH
7.10 OTHER STIMULATION TYPES
8 NEUROMODULATION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION
8.2.1 CHRONIC PAIN
8.2.1.1 High incidence of chronic pain among geriatric population to support market growth
8.2.2 FAILED BACK SURGERY SYNDROME
8.2.2.1 Increasing number of spinal surgeries to aid market growth
8.2.3 ISCHEMIA
8.2.3.1 High effectiveness of neuromodulation to boost effectiveness for ischemia treatment
8.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION
8.3.1 PARKINSON’S DISEASE
8.3.1.1 Development of advanced solutions and increased R&D to improve market growth
8.3.2 TREMORS
8.3.2.1 Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market
8.3.3 DEPRESSION
8.3.3.1 Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment
8.3.4 OTHER DEEP BRAIN STIMULATION APPLICATIONS
8.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION
8.4.1 URINE INCONTINENCE
8.4.1.1 High incidence of urine incontinence to offer growth opportunities for market players
8.4.2 FECAL INCONTINENCE
8.4.2.1 Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence
8.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION
8.5.1 EPILEPSY
8.5.1.1 Low risk with device implantation and long-lasting battery life to aid market growth
8.5.2 OTHER VAGUS NERVE STIMULATION APPLICATIONS
8.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
8.6.1 GASTROPARESIS
8.6.1.1 Reduced hospitalization time associated with sastroparesis treatment to augment market growth
8.6.2 OBESITY
8.6.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market growth
8.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
8.7.1 TREATMENT-RESISTANT DEPRESSION
8.7.1.1 High prevalence of chronic and recurrent depression to augment market growth
8.7.2 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS
8.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
8.8.1 DEPRESSION
8.8.1.1 Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients
8.8.2 MIGRAINE
8.8.2.1 High prevalence of migraines to support market growth
8.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
8.9.1 INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS
8.10 OTHER APPLICATIONS
9 NEUROMODULATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & AMBULATORY SURGERY CENTERS
9.2.1 ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH
9.3 CLINICS & PHYSIOTHERAPY CENTERS
9.3.1 NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION
9.4 OTHER END USERS
10 NEUROMODULATION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American neuromodulation market during forecast period
10.2.3 CANADA
10.2.3.1 Increasing neurological disorder rates and rising government funding to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Advanced surgical innovations and favorable reimbursement policies to drive market
10.3.3 FRANCE
10.3.3.1 Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques
10.3.4 UK
10.3.4.1 Increased public & private sector healthcare expenditure and investments to fuel market growth
10.3.5 ITALY
10.3.5.1 Rising cases of dementia and Alzheimer’s among geriatric population to spur market growth
10.3.6 SPAIN
10.3.6.1 Favorable government-led healthcare initiatives to support market growth
10.3.7 RUSSIA
10.3.7.1 Shifting demographic landscape and escalating neurological health needs to drive demand
10.3.8 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand
10.4.3 JAPAN
10.4.3.1 Innovative healthcare delivery and advanced infrastructure landscape to augment market growth
10.4.4 INDIA
10.4.4.1 Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth
10.4.5 AUSTRALIA
10.4.5.1 Increasing cases of depressive and post-traumatic stress disorders to propel market demand
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Improvements in healthcare infrastructure to aid market growth
10.5.3 MEXICO
10.5.3.1 Expanding healthcare awareness and growing burden of neurological disorders to favor market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET
11.3 REVENUE ANALYSIS, 2020–2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Technology footprint
11.5.5.4 Stimulation type footprint
11.5.5.5 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of startups/SMEs
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 COMPANY VALUATION
11.7.2 FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MEDTRONIC
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 BOSTON SCIENTIFIC CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 ABBOTT
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches and approvals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 LIVANOVA PLC
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 NEVRO CORP.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 NEUROPACE, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 BIOVENTUS
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product approvals
12.1.8 ELECTROCORE, INC.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.8.3.2 Deals
12.1.9 HELIUS MEDICAL TECHNOLOGIES, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.10 NEURONETICS
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Deals
12.2 OTHER PLAYERS
12.2.1 NEUROSIGMA, INC.
12.2.2 SOTERIX MEDICAL INC.
12.2.3 SYNAPSE BIOMEDICAL INC.
12.2.4 ALEVA NEUROTHERAPEUTICS
12.2.5 THERANICA BIO-ELECTRONICS LTD.
12.2.6 GIMER MEDICAL
12.2.7 NALU MEDICAL, INC.
12.2.8 MICROTRANSPONDER INC.
12.2.9 MAGSTIM
12.2.10 AMBER THERAPEUTICS
12.2.11 TVNS TECHNOLOGIES GMBH
12.2.12 BIOWAVE
12.2.13 BIOTRONIK
12.2.14 SALUDA MEDICAL PTY LTD.
12.2.15 SPR
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 NEUROMODULATION MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 NEUROMODULATION MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 MARKET ASSUMPTIONS IN NEUROMODULATION MARKET
TABLE 4 RISK ANALYSIS IN NEUROMODULATION MARKET
TABLE 5 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES
TABLE 6 AVERAGE SELLING PRICING TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 9 ROLE OF KEY PLAYERS IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
TABLE 10 LIST OF KEY PATENTS IN NEUROMODULATION MARKET, 2022–2025
TABLE 11 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN NEUROMODULATION MARKET, JANUARY 2025–DECEMBER 2026
TABLE 14 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
TABLE 15 NATIONAL MEDICAL PRODUCT ADMINISTRATION (NMPA) MEDICAL DEVICES CLASSIFICATION
TABLE 16 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 IMPACT OF PORTER’S FIVE FORCES ON NEUROMODULATION MARKET
TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 24 KEY BUYING CRITERIA, BY END USER
TABLE 25 KEY COMPANIES IMPLEMENTING AI IN NEUROMODULATION MARKET
TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 27 NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 28 INTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 34 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 39 SPINAL CORD STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 40 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 41 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45 DEEP BRAIN STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 46 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 47 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49 ASIA PACIFIC: NEUROMODULATION FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 SACRAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 52 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 53 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57 VAGUS NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 58 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 59 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63 GASTRIC NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 64 NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 EUROPE: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 70 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75 TRANSCRANIAL MAGNETIC STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 76 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 77 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 RESPIRATORY ELECTRICAL STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 82 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 83 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 OTHER STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 88 NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY REGION, 2023–2030 (USD MILLION)
TABLE 89 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90 EUROPE: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 94 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2023–2030 (USD MILLION)
TABLE 95 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96 EUROPE: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2023–2030 (USD MILLION)
TABLE 100 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 EUROPE: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2023–2030 (USD MILLION)
TABLE 105 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 EUROPE: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 110 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2023–2030 (USD MILLION)
TABLE 111 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 EUROPE: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2023–2030 (USD MILLION)
TABLE 116 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117 EUROPE: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 121 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 EUROPE: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125 OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 126 NORTH AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 EUROPE: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 ASIA PACIFIC: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 LATIN AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)
TABLE 132 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133 EUROPE: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)
TABLE 137 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138 EUROPE: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 142 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2023–2030 (USD MILLION)
TABLE 143 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144 EUROPE: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146 LATIN AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 148 NORTH AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 EUROPE: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150 ASIA PACIFIC: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151 LATIN AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 153 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 154 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158 GLOBAL NUMBERS OF ADULTS WITH OBESITY (BMI ?30 KG/M2 ), BY REGION (BILLION)
TABLE 159 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2023–2030 (USD MILLION)
TABLE 160 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 165 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 166 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 LATIN AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 171 NORTH AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172 EUROPE: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 ASIA PACIFIC: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 LATIN AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 176 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 177 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2023–2030 (USD MILLION)
TABLE 182 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 187 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191 OTHER NEUROMODULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 192 NORTH AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193 EUROPE: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194 ASIA PACIFIC: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 LATIN AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196 NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 197 NUMBER OF HOSPITALS PER CAPITA, BY COUNTRY, 2024
TABLE 198 NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 199 NORTH AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200 EUROPE: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201 ASIA PACIFIC: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 LATIN AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 204 NORTH AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 EUROPE: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206 ASIA PACIFIC: NEUROMODULATION FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207 LATIN AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208 NEUROMODULATION MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 209 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, 2023–2030 (USD MILLION)
TABLE 210 EUROPE: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 213 NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 214 NORTH AMERICA: KEY MACROINDICATORS
TABLE 215 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 217 NORTH AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 218 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 219 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 220 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 221 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 222 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 223 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 224 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 225 NORTH AMERICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 226 US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 227 US: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 228 US: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 229 US: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 230 US: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 231 US: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 232 US: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 233 US: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 234 US: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 235 US: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 236 CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 237 CANADA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 238 CANADA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 239 CANADA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 240 CANADA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 241 CANADA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 242 CANADA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 243 CANADA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 244 CANADA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 245 CANADA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 246 EUROPE: KEY MACROINDICATORS
TABLE 247 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248 EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 249 EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 250 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 251 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 252 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 253 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 254 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 255 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 257 EUROPE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 258 GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 259 GERMANY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 260 GERMANY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 261 GERMANY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 262 GERMANY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 263 GERMANY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 264 GERMANY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265 GERMANY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 266 GERMANY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 267 GERMANY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 268 FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 269 FRANCE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 270 FRANCE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 271 FRANCE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 272 FRANCE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 273 FRANCE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 274 FRANCE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 275 FRANCE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 276 FRANCE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 277 FRANCE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 278 UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 279 UK: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 280 UK: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281 UK: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 282 UK: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 283 UK: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 284 UK: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 285 UK: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 286 UK: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 287 UK: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 288 ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 289 ITALY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 290 ITALY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 291 ITALY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 292 ITALY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 293 ITALY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 294 ITALY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 295 ITALY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 296 ITALY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 297 ITALY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 298 SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 299 SPAIN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 300 SPAIN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 301 SPAIN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 302 SPAIN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 303 SPAIN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 304 SPAIN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305 SPAIN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 306 SPAIN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 307 SPAIN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308 RUSSIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 309 RUSSIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 310 RUSSIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 311 RUSSIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 312 RUSSIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 313 RUSSIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 314 RUSSIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 315 RUSSIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 316 RUSSIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 317 RUSSIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 318 REST OF EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 1 NEUROMODULATION MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 NEUROMODULATION MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 MARKET ASSUMPTIONS IN NEUROMODULATION MARKET
TABLE 4 RISK ANALYSIS IN NEUROMODULATION MARKET
TABLE 5 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES
TABLE 6 AVERAGE SELLING PRICING TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 9 ROLE OF KEY PLAYERS IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
TABLE 10 LIST OF KEY PATENTS IN NEUROMODULATION MARKET, 2022–2025
TABLE 11 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN NEUROMODULATION MARKET, JANUARY 2025–DECEMBER 2026
TABLE 14 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
TABLE 15 NATIONAL MEDICAL PRODUCT ADMINISTRATION (NMPA) MEDICAL DEVICES CLASSIFICATION
TABLE 16 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 IMPACT OF PORTER’S FIVE FORCES ON NEUROMODULATION MARKET
TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 24 KEY BUYING CRITERIA, BY END USER
TABLE 25 KEY COMPANIES IMPLEMENTING AI IN NEUROMODULATION MARKET
TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 27 NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 28 INTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 34 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 39 SPINAL CORD STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 40 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 41 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45 DEEP BRAIN STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 46 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 47 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49 ASIA PACIFIC: NEUROMODULATION FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 SACRAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 52 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 53 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57 VAGUS NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 58 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 59 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63 GASTRIC NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 64 NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 EUROPE: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 70 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75 TRANSCRANIAL MAGNETIC STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 76 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 77 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 RESPIRATORY ELECTRICAL STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 82 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 83 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 OTHER STIMULATION DEVICES OFFERED BY KEY PLAYERS
TABLE 88 NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY REGION, 2023–2030 (USD MILLION)
TABLE 89 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90 EUROPE: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 94 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2023–2030 (USD MILLION)
TABLE 95 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96 EUROPE: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2023–2030 (USD MILLION)
TABLE 100 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 EUROPE: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2023–2030 (USD MILLION)
TABLE 105 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 EUROPE: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 110 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2023–2030 (USD MILLION)
TABLE 111 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 EUROPE: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2023–2030 (USD MILLION)
TABLE 116 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117 EUROPE: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 121 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 EUROPE: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125 OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 126 NORTH AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 EUROPE: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 ASIA PACIFIC: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 LATIN AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)
TABLE 132 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133 EUROPE: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)
TABLE 137 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138 EUROPE: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 142 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2023–2030 (USD MILLION)
TABLE 143 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144 EUROPE: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146 LATIN AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 148 NORTH AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 EUROPE: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150 ASIA PACIFIC: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151 LATIN AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 153 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 154 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158 GLOBAL NUMBERS OF ADULTS WITH OBESITY (BMI ?30 KG/M2 ), BY REGION (BILLION)
TABLE 159 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2023–2030 (USD MILLION)
TABLE 160 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 165 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 166 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 LATIN AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 171 NORTH AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172 EUROPE: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 ASIA PACIFIC: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 LATIN AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 176 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION)
TABLE 177 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2023–2030 (USD MILLION)
TABLE 182 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 187 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191 OTHER NEUROMODULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 192 NORTH AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193 EUROPE: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194 ASIA PACIFIC: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 LATIN AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196 NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 197 NUMBER OF HOSPITALS PER CAPITA, BY COUNTRY, 2024
TABLE 198 NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 199 NORTH AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200 EUROPE: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201 ASIA PACIFIC: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 LATIN AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 204 NORTH AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 EUROPE: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206 ASIA PACIFIC: NEUROMODULATION FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207 LATIN AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208 NEUROMODULATION MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 209 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, 2023–2030 (USD MILLION)
TABLE 210 EUROPE: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 213 NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 214 NORTH AMERICA: KEY MACROINDICATORS
TABLE 215 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 217 NORTH AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 218 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 219 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 220 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 221 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 222 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 223 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 224 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 225 NORTH AMERICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 226 US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 227 US: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 228 US: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 229 US: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 230 US: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 231 US: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 232 US: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 233 US: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 234 US: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 235 US: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 236 CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 237 CANADA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 238 CANADA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 239 CANADA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 240 CANADA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 241 CANADA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 242 CANADA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 243 CANADA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 244 CANADA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 245 CANADA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 246 EUROPE: KEY MACROINDICATORS
TABLE 247 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248 EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 249 EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 250 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 251 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 252 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 253 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 254 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 255 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 257 EUROPE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 258 GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 259 GERMANY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 260 GERMANY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 261 GERMANY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 262 GERMANY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 263 GERMANY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 264 GERMANY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265 GERMANY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 266 GERMANY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 267 GERMANY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 268 FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 269 FRANCE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 270 FRANCE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 271 FRANCE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 272 FRANCE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 273 FRANCE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 274 FRANCE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 275 FRANCE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 276 FRANCE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 277 FRANCE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 278 UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 279 UK: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 280 UK: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281 UK: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 282 UK: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 283 UK: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 284 UK: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 285 UK: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 286 UK: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 287 UK: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 288 ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 289 ITALY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 290 ITALY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 291 ITALY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 292 ITALY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 293 ITALY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 294 ITALY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 295 ITALY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 296 ITALY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 297 ITALY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 298 SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 299 SPAIN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 300 SPAIN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 301 SPAIN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 302 SPAIN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 303 SPAIN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 304 SPAIN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305 SPAIN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 306 SPAIN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 307 SPAIN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308 RUSSIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 309 RUSSIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)
TABLE 310 RUSSIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 311 RUSSIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 312 RUSSIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 313 RUSSIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 314 RUSSIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 315 RUSSIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 316 RUSSIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 317 RUSSIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 318 REST OF EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
The global neuromodulation market is estimated at $3.65 Billion in 2015, and is projected to reach $6.20 Billion by 2020, at a CAGR of 11.2% during the forecast period.
The global neuromodulation market is segmented on the basis of technology, application, and region.
Factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by players, and expanded target applications and new indications are driving the growth of this market. However, factors such as unfavourable reimbursement scenario and lack of trained professionals are hindering its market growth.
Some of the major players in the global Neuromodulation Market are
- Medtronic, Inc. (U.S.)
- Boston Scientific Corporation (U.S.)
- St. Jude Medical, Inc. (U.S.)
- Synapse Biomedical, Inc. (U.S.)
- Nevro Corporation (U.S.)
- Neurosigma, Inc. (U.S.)
Based on technology, the neuromodulation market is segmented into internal neuromodulation and external neuromodulation. Internal neuromodulation is further segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). External neuromodulation is categorized into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and respiratory electrical stimulation (RES).
Based on application, the neuromodulation market is segmented into technology-wise applications, such as spinal cord stimulation (chronic pain, failed back surgery, ischemia); deep brain stimulation (Parkinsons disease, tremor, depression, others); sacral nerve stimulation (urine incontinence, fecal incontinence); vagus nerve stimulation (epilepsy, others); gastric electrical stimulation (gastro paresis, obesity); transcutaneous electrical nerve stimulation (treatment resistant depression, others); and transcranial magnetic stimulation (depression, migraine headaches).
On the basis of region, the market is divided into North America, Europe, Asia-Pacific, and rest of the world (RoW). The rest of the world region comprises Latin America, the Middle East, and Africa. North America is expected to account for the largest share of the neuromodulation market, followed by Europe, Asia-Pacific, and rest of the world (RoW) in 2015.
